Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4913305 | 0.68 | — | — | |
| SCHEMBL627003 | 0.62 | ALDH1A1 (0.31) | ALDH1A1 | |
| SCHEMBL9816260 | 0.61 | — | — | |
| SCHEMBL289021 | 0.59 | — | — | |
| SCHEMBL29663753 | 0.57 | — | — | |
| SCHEMBL4269106 | 0.57 | — | — | |
| SCHEMBL6573461 | 0.57 | — | — | |
| SCHEMBL627902 | 0.56 | — | — | |
| SCHEMBL9902167 | 0.56 | — | — | |
| SCHEMBL9836014 | 0.56 | ALDH1A1 (0.54) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8734818-B2 | Methods for treating cognitive/attention deficit disorders using tetrahydroindolone analogues and derivatives | SPECTRUM PHARMACEUTICALS, INC. (US) | 2014-05-27 | — | — | US | disclosed |
| US-20130225648-A1 | Methods for Treating Cognitive/Attention Deficit Disorders Using Tetrahydroindolone Analogues and Derivatives | SPECTRUM PHARMACEUTICALS, INC. (US) | 2013-08-29 | — | — | US | disclosed |
| US-8377456-B2 | Methods for treating cognitive/attention deficit disorders using tetrahydroindolone analogues and derivatives | SPECTRUM PHARMACEUTICALS, INC. (US) | 2013-02-19 | — | — | US | disclosed |
| US-20120070385-A1 | Methods for Treating Cognitive/Attention Deficit Disorders Using Tetrahydroindolone Analogues and Derivatives | SPECTRUM PHARMACEUTICALS, INC. (US) | 2012-03-22 | — | — | US | disclosed |
| US-8063233-B2 | Methods for treating cognitive/attention deficit disorders using tetrahydroindolone analogues and derivatives | SPECTRUM PHARMACEUTICALS INC. (US) | 2011-11-22 | — | — | US | disclosed |
| EP-1383742-B1 | SYNTHESIS AND METHODS OF USE OF TETRAHYDROINDOLONE ANALOGUES AND DERIVATIVES | SPECTRUM PHARMACEUTICALS INC (US) | 2010-10-27 | — | — | EP | disclosed |
| US-20090192319-A1 | METHODS FOR TREATING COGNITIVE /ATTENTION DEFICIT DISORDERS USING TETRAHYDROINDOLONE ANALOGUES AND DERIVATIVES | SPECTRUM PHARMACEUTICALS, INC. (US) | 2009-07-30 | — | — | US | disclosed |
| US-6982269-B2 | Methods for treating cognitive/attention deficit disorders using tetrahydroindolone analogues and derivatives | SPECTRUM PHARMACEUTICALS, INC. (US) | 2006-01-03 | — | — | US | disclosed |
| US-20050096317-A1 | Methods for treating cognitive/attention deficit disorders using tetrahydroindolone analogues and derivatives | NEOTHERAPEUTICS, INC. (US) | 2005-05-05 | — | — | US | disclosed |
| US-6759427-B2 | SUCH AS 4-(3-(4-OXO-4,5,6,7-TETRAHYDROINDOLON-1-YL)PROPIONYL-AMINO)BENZOIC ACID WHICH IMPROVES NEURONAL FUNCTION, REGENERATION, NEUROGENESIS, AND HAS NEUROPROTECTIVE ACTIVITY | SPECTRUM PHARMACEUTICALS, INC. | 2004-07-06 | — | — | US | disclosed |
| EP-1383742-A1 | SYNTHESIS AND METHODS OF USE OF TETRAHYDROINDOLONE ANALOGUES AND DERIVATIVES | Neotherapeutics, Inc. (US) | 2004-01-28 | — | — | EP | disclosed |
| US-20030022892-A1 | Methods for treating cognitive/attention deficit disorders using tetrahydroindolone analogues and derivatives | SPECTRUM PHARMACEUTICALS, INC. | 2003-01-30 | — | — | US | disclosed |
| US-20020198218-A1 | Synthesis and methods of use of tetrahydroindolone analogues and derivatives | SPECTRUM PHARMACEUTICALS, INC. | 2002-12-26 | — | — | US | disclosed |
| WO-2002085856-A1 | SYNTHESIS AND METHODS OF USE OF TETRAHYDROINDOLONE ANALOGUES AND DERIVATIVES | NEOTHERAPEUTICS, INC. (US) | 2002-10-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020198218-A1 | Synthesis and methods of use of tetrahydroindolone analogues and derivatives | CYP11B1, CYP11B2, CYP4A11 | ALDH1A1 1053/4885 |
| US-20130225648-A1 | Methods for Treating Cognitive/Attention Deficit Disorders Using Tetrahydroindolone Analogues and Derivatives | DRD2, DRD4, DRD1 | ALDH1A1 846/4885 |
| US-20050096317-A1 | Methods for treating cognitive/attention deficit disorders using tetrahydroindolone analogues and derivatives | DRD4, DRD2, DRD1 | ALDH1A1 809/4885 |
| US-20090192319-A1 | METHODS FOR TREATING COGNITIVE /ATTENTION DEFICIT DISORDERS USING TETRAHYDROINDOLONE ANALOGUES AND DERIVATIVES | DRD2, DRD4, DRD1 | ALDH1A1 846/4885 |
| US-20120070385-A1 | Methods for Treating Cognitive/Attention Deficit Disorders Using Tetrahydroindolone Analogues and Derivatives | HTR2C, HSD11B2, DRD4 | ALDH1A1 572/4885 |
| US-20030022892-A1 | Methods for treating cognitive/attention deficit disorders using tetrahydroindolone analogues and derivatives | DRD4, DRD2, DRD1 | ALDH1A1 645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.